The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1384
Deferiprone (Ferriprox) for Iron Overload
The full article is available to subscribers Subscriber Login   
Revised 2/27/12: The second sentence in the conclusion has been changed to fix a grammatical error.

The FDA has approved deferiprone (de fer’ i prone; Ferriprox – ApoPharma), an oral chelating agent available in Europe since 1999, for use as a second-line treatment of iron overload due to blood transfusions (transfusional hemosiderosis) in patients with thalassemia. Two other iron chelating agents, deferoxamine (Desferal, and others), which is usually administered subcutaneously, and oral deferasirox (Exjade), are available for use as first-line therapy in the US.

IRON OVERLOAD — Iron overload is a complication of long-term transfusion therapy in patients with diseases such as beta-thalassemia, sickle cell anemia and myelodysplastic syndrome. It can damage the liver, pancreas, other endocrine organs and the heart.1 Cardiac damage can lead to arrhythmias, congestive heart failure and death. Deferoxamine can prevent these effects, but ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Deferiprone (Ferriprox) for Iron Overload
Article code: 1384c
 Electronic, downloadable article - $25